ECOR Stock Overview
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.61|
|52 Week High||US$1.30|
|52 Week Low||US$0.27|
|1 Month Change||1.65%|
|3 Month Change||55.06%|
|1 Year Change||-35.19%|
|3 Year Change||-66.48%|
|5 Year Change||n/a|
|Change since IPO||-96.93%|
Recent News & Updates
electroCore sees Q2 revenue estimate higher than consensus
electroCore (NASDAQ:ECOR) expects Q2 revenue to come in more than $2.1M which is a 11% increase from Q1 2022 and ~65% Y/Y growth; this is compared to analysts consensus estimates of $2M. During the quarter, the company expects to recognize revenue of ~$1.2M (vs. $1.26M in Q1 of 2022) post the Department of Veterans Affairs and Department of Defense originating prescriptions for company's gammaCore products. It sees commercial revenue of ~$465K dominated by cash pay initiatives and representing ~68% Q/Q increase and 347% Y/Y growth. Revenue outside of U.S. seen at ~$466K marking ~53% Q/Q increase and ~20% Y/Y increase. Q2 ended with ~$26.6M of cash and equivalents, compared to $29.9M as of the end of Q1 of 2022. Q2 earnings scheduled for August 2022. Shares trading 5.1% higher premarket.
|ECOR||US Medical Equipment||US Market|
Return vs Industry: ECOR underperformed the US Medical Equipment industry which returned -20.7% over the past year.
Return vs Market: ECOR underperformed the US Market which returned -8.9% over the past year.
|ECOR Average Weekly Movement||11.6%|
|Medical Equipment Industry Average Movement||9.4%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: ECOR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ECOR's weekly volatility (12%) has been stable over the past year.
About the Company
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years.
electroCore Fundamentals Summary
|ECOR fundamental statistics|
Is ECOR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ECOR income statement (TTM)|
|Cost of Revenue||US$1.37m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.28|
|Net Profit Margin||-282.32%|
How did ECOR perform over the long term?See historical performance and comparison
Is ECOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ECOR?
Other financial metrics that can be useful for relative valuation.
|What is ECOR's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ECOR's PS Ratio compare to its peers?
|ECOR PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
DCTH Delcath Systems
PEYE Precision Optics Corporation
Price-To-Sales vs Peers: ECOR is expensive based on its Price-To-Sales Ratio (6.2x) compared to the peer average (4x).
Price to Earnings Ratio vs Industry
How does ECOR's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: ECOR is expensive based on its Price-To-Sales Ratio (6.2x) compared to the US Medical Equipment industry average (4.5x)
Price to Sales Ratio vs Fair Ratio
What is ECOR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||6.2x|
|Fair PS Ratio||11.3x|
Price-To-Sales vs Fair Ratio: ECOR is good value based on its Price-To-Sales Ratio (6.2x) compared to the estimated Fair Price-To-Sales Ratio (11.3x).
Share Price vs Fair Value
What is the Fair Price of ECOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ECOR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ECOR's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is electroCore forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ECOR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ECOR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ECOR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ECOR's revenue (38.8% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: ECOR's revenue (38.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ECOR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has electroCore performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ECOR is currently unprofitable.
Growing Profit Margin: ECOR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ECOR is unprofitable, and losses have increased over the past 5 years at a rate of 2.5% per year.
Accelerating Growth: Unable to compare ECOR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ECOR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).
Return on Equity
High ROE: ECOR has a negative Return on Equity (-73.08%), as it is currently unprofitable.
Discover strong past performing companies
How is electroCore's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ECOR's short term assets ($29.1M) exceed its short term liabilities ($5.6M).
Long Term Liabilities: ECOR's short term assets ($29.1M) exceed its long term liabilities ($664.0K).
Debt to Equity History and Analysis
Debt Level: ECOR is debt free.
Reducing Debt: ECOR has no debt compared to 5 years ago when its debt to equity ratio was 14.6%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ECOR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ECOR has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 15.3% each year.
Discover healthy companies
What is electroCore current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ECOR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ECOR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ECOR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ECOR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ECOR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dan Goldberger (63 yo)
Mr. Daniel S. Goldberger, also known as Dan, has been Chief Executive Officer and Director of electroCore, Inc. since October 1, 2019. Mr. Goldberger served as Executive Chairman at Repro Med Systems, Inc....
CEO Compensation Analysis
Compensation vs Market: Dan's total compensation ($USD1.30M) is above average for companies of similar size in the US market ($USD753.27K).
Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.
Experienced Management: ECOR's management team is considered experienced (2.7 years average tenure).
Experienced Board: ECOR's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ECOR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.
electroCore, Inc.'s employee growth, exchange listings and data sources
- Name: electroCore, Inc.
- Ticker: ECOR
- Exchange: NasdaqCM
- Founded: 2005
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$43.384m
- Shares outstanding: 71.12m
- Website: https://www.electrocore.com
Number of Employees
- electroCore, Inc.
- 200 Forge Way
- Suite 205
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/17 00:00|
|End of Day Share Price||2022/08/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.